Download PDF
TumorDiagnostik & Therapie 2020; 41(03): 174-177
DOI: 10.1055/a-1120-4334
Thieme Onkologie aktuell

Nichtkleinzelliges Lungenkarzinom – doppelte Resistenzentwicklung

Non-Small Cell Lung Cancer – Development of Parallel Mechanisms of Resistance
M. Moeller
1   Klinik für Innere Medizin II, Krankenhaus Martha-Maria Halle-Dölau
,
U. Siebolts
2   Insitut für Pathologie, Universitätsklinikum Halle (Saale)
,
C. Wickenhauser
2   Insitut für Pathologie, Universitätsklinikum Halle (Saale)
,
W. Schuette
1   Klinik für Innere Medizin II, Krankenhaus Martha-Maria Halle-Dölau
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Erworbene Resistenzen gegenüber Tyrosinkinase-Inhibitoren beim nichtkleinzelligen Lungenkarzinom entwickeln sich nach etwa 9–12 Monaten. In etwa 60 % der Fälle entstehen diese durch eine sekundäre EGFR-T790M-Resistenzmutation. In dieser Kasuistik wird der Fall einer Patientin mit einer Mutation im EGFR Exon 19 beschrieben. Es entwickeln sich unter TKI-Therapie 2 parallele Resistenzmechanismen. Zum einen eine T790M-Resistenzmutation, zum anderen die Transformation in ein kleinzelliges neuroendokrines Karzinom. Unter der Therapie mit Osimertinib sowie paralleler Chemotherapie mit Carboplatin und Etoposid konnte nach 2 Zyklen eine partielle Remission erzielt werden.

Abstract

Acquired resistances to tyrosine kinase inhibitors in nonsmall cell lung cancer develop after 9–12 months. In 60 % of the cases these resistances arise because of a secondary EGFR-T790 M resistance mutation. This report is describing the case of a patient who developed parallel two different mechanisms of resistance: A T790 M resistance mutation and a transformation into a small cell neuroendocrine cancer. Under therapy with Osimertinib and chemotherapy with carboplatin and etoposide the tumor responsed partially.



Publication History

Received: 07 December 2017

Accepted: 04 January 2018

Article published online:
01 April 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30
    CrossrefPubMedGoogle Scholar
  • 2 Mok TS, Wu YL, Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957
    CrossrefPubMedGoogle Scholar
  • 3 Sequist LV, Waltman BA, Dias-Santagata D. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26
    PubMedGoogle Scholar
  • 4 Oser MG, Niederst MJ, Sequist LV. et al. Transformation from nonsmall-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 2015; 16: e165-e172
    CrossrefPubMedGoogle Scholar
  • 5 Oxnard GR, Arcila ME, Sima CS. et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011; 17: 1616-1622
    CrossrefPubMedGoogle Scholar
  • 6 Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014; 11: 473-481
    CrossrefPubMedGoogle Scholar
  • 7 Baglivo S, Ludovini V, Sidoni A. et al. Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. Mayo Clin Proc 2017; 92 (08) 1304-1311
    CrossrefPubMedGoogle Scholar
  • 8 Yu HA, Arcila ME, Rekhtman N. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-2247
    CrossrefPubMedGoogle Scholar
  • 9 Engelman JA, Zejnullahu K, Mitsudomi T. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043
    CrossrefPubMedGoogle Scholar
  • 10 Zakowski MF, Ladanyi M, Kris MG. The Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006; 355: 213-215
    CrossrefPubMedGoogle Scholar
  • 11 Van Riel S, Thunnissen E, Heideman D. et al. A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation. Ann Oncol 2012; 23: 3188-3189
    CrossrefPubMedGoogle Scholar
  • 12 Morinaga R, Okamoto I, Furuta K. et al. Sequential occurrence of nonsmall cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007; 58: 411-413
    CrossrefPubMedGoogle Scholar
  • 13 Norkowski E, Ghigna MR, Lacroix L. et al. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology. J Thorac Oncol 2013; 8: 1265-1271
    CrossrefPubMedGoogle Scholar
  • 14 Watanabe S, Sone T, Matsui T. et al. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma. Lung Cancer 2013; 82: 370-372
    CrossrefPubMedGoogle Scholar
  • 15 Popat S, Wotherspoon A, Nutting CM. et al. Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer 2013; 80: 1-4
    CrossrefPubMedGoogle Scholar